Oncoinvent (ONCIN) DNB Carnegie Nordic Healthcare Conference presentation summary

Unique radiopharmaceutical approach

• Utilizes targeted, non-biological, receptor-independent alpha therapy for peritoneal metastases, combining 224Ra with CaCO3 microparticles for localized, high-dose radiation delivery.

• RadspherinⓇ is retained in the peritoneum, delivering 75% of its radiation dose in the first week and sparing surrounding healthy tissue.

• Shelf life of 8 days enables centralized manufacturing and distribution.

Unmet medical need and clinical focus

• Peritoneal metastases are common in ovarian and colorectal cancers, with high relapse rates after surgery and limited systemic therapy efficacy.

• Local control in the peritoneum is crucial for improving survival, as most recurrences are confined to this compartment.

• RadspherinⓇ addresses a high unmet need with limited competition in these indications.

Clinical development and efficacy signals

• Phase 1/2a studies in ovarian and colorectal cancer show strong safety and promising efficacy, with lower peritoneal recurrence rates compared to historical controls.

• Ovarian cancer: 10% peritoneal recurrence at 24 months vs 30% historical; overall recurrence 30% vs ~55-60%.

• Colorectal cancer: 28% peritoneal recurrence at 18 months vs 50% historical.